Bevin Manuelpillai, Mackenzie Zendt, Emma Chang-Rabley, Emily Ricotta
BACKGROUND Immune-deficient/disordered people (IDP) are underrepresented in COVID-19 studies. Specifically, there is limited research on post-SARS-CoV-2 infection outcomes, including viral persistence and long-term sequelae in these populations. OBJECTIVES This review aimed to examine the published literature on the occurrence of persistent SARS-CoV-2 positivity, relapse, reinfections, variant coinfection, and post-acute sequelae of COVID-19 in IDP. While the available literature largely centered on those with secondary immunodeficiencies, studies on people with inborn errors of immunity are also included. SOURCES PubMed was searched using Medical Subject Headings (MeSH) terms to identify relevant articles from the last four years. Articles on primary and secondary immunodeficiencies were chosen and a special emphasis was placed on including articles that studied people with inborn errors of immunity. The absence of extensive cohort studies including these individuals has limited most articles in this review to case reports, whereas the articles focusing on secondary immunodeficiencies include larger cohort, case-control, and cross-sectional studies. Articles focusing solely on HIV/AIDS were excluded. CONTENT Scientific literature suggests that IDP of any age are more likely to experience persistent SARS-CoV-2 infections. While adult IDP exhibit a higher rate of post-acute sequelae of COVID-19 (PASC), milder COVID-19 infections in children may reduce their risk of experiencing PASC. Reinfections and coinfections may occur at a slightly higher rate in IDP than the general population. IMPLICATIONS While IDP experience increased viral persistence and inter-host evolution, it is unlikely that enough evidence can be generated at the population-level to support or refute the hypothesis that infections in IDP are significantly more likely to result in variants of concern than infections in the general population. Additional research on the relationship between viral persistence and the rate of long-term sequelae in IDP could inform the understanding of the immune response to SARS-CoV-2 in IDP and the general population.
{"title":"\"Stuck in pandemic uncertainty: A review of the persistent Effects of COVID-19 infection in immune deficient people\".","authors":"Bevin Manuelpillai, Mackenzie Zendt, Emma Chang-Rabley, Emily Ricotta","doi":"10.2139/ssrn.4698243","DOIUrl":"https://doi.org/10.2139/ssrn.4698243","url":null,"abstract":"BACKGROUND\u0000Immune-deficient/disordered people (IDP) are underrepresented in COVID-19 studies. Specifically, there is limited research on post-SARS-CoV-2 infection outcomes, including viral persistence and long-term sequelae in these populations.\u0000\u0000\u0000OBJECTIVES\u0000This review aimed to examine the published literature on the occurrence of persistent SARS-CoV-2 positivity, relapse, reinfections, variant coinfection, and post-acute sequelae of COVID-19 in IDP. While the available literature largely centered on those with secondary immunodeficiencies, studies on people with inborn errors of immunity are also included.\u0000\u0000\u0000SOURCES\u0000PubMed was searched using Medical Subject Headings (MeSH) terms to identify relevant articles from the last four years. Articles on primary and secondary immunodeficiencies were chosen and a special emphasis was placed on including articles that studied people with inborn errors of immunity. The absence of extensive cohort studies including these individuals has limited most articles in this review to case reports, whereas the articles focusing on secondary immunodeficiencies include larger cohort, case-control, and cross-sectional studies. Articles focusing solely on HIV/AIDS were excluded.\u0000\u0000\u0000CONTENT\u0000Scientific literature suggests that IDP of any age are more likely to experience persistent SARS-CoV-2 infections. While adult IDP exhibit a higher rate of post-acute sequelae of COVID-19 (PASC), milder COVID-19 infections in children may reduce their risk of experiencing PASC. Reinfections and coinfections may occur at a slightly higher rate in IDP than the general population.\u0000\u0000\u0000IMPLICATIONS\u0000While IDP experience increased viral persistence and inter-host evolution, it is unlikely that enough evidence can be generated at the population-level to support or refute the hypothesis that infections in IDP are significantly more likely to result in variants of concern than infections in the general population. Additional research on the relationship between viral persistence and the rate of long-term sequelae in IDP could inform the understanding of the immune response to SARS-CoV-2 in IDP and the general population.","PeriodicalId":504942,"journal":{"name":"Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases","volume":"22 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140401482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-11-01DOI: 10.1111/j.1469-0691.2009.03155.x
R Krausse, S Schubert
Antimicrobial resistance in genital mycoplasmas is increasing and shows global variation. We determined the susceptibilities of 469 mycoplamas, comprising 290 Mycoplasma hominis and 179 ureaplasma isolates collected during 1983 and 1989-2004, to eleven antibacterials by agar dilution. Additionally, we analyzed the results of routine E-testing during 2005-2008. Doxycycline was the most active tetracycline with (MIC₉₀ of 1 and 8 mg/L for ureaplasmas and M. hominis, respectively. Significantly more M. hominis isolates (approximately 10-13%) than ureaplasmas (approximately 1-3%) were resistant to tetracyclines. Ofloxacin was effective against both species (>95% susceptibility). Ciprofloxacin was moderately active against M. hominis and less active against ureaplasmas (70.3% and 35.2% susceptibility, respectively). Clarithromycin and josamycin were the most potent macrolides (MIC₉₀ of 0.5 mg/L) against ureaplasmas. Erythromycin had the lowest activity (MIC₉₀ of 8 mg/L) against ureaplasmas like clindamycin which was the most potent agent against M. hominis. Cross-resistance was found between tetracyclines (53-93%), macrolides and erythromycin (70-100%), and between erythromycin and ciprofloxacin (43-55%). M. hominis became more resistant to tetracyclines and fluoroquinolones between 1989 and 2004, although there was little change during 2005-2008. Ureaplasmas became more resistant to cipfloxacin during 1997 – 2004 and showed high resistance rates to erythromycin during 1989-2008. Doxycycline is still the drug of first-choice for the treatment of ureaplasmal infections and may be used for co-infection with M. hominis.
{"title":"In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years.","authors":"R Krausse, S Schubert","doi":"10.1111/j.1469-0691.2009.03155.x","DOIUrl":"https://doi.org/10.1111/j.1469-0691.2009.03155.x","url":null,"abstract":"<p><p>Antimicrobial resistance in genital mycoplasmas is increasing and shows global variation. We determined the susceptibilities of 469 mycoplamas, comprising 290 Mycoplasma hominis and 179 ureaplasma isolates collected during 1983 and 1989-2004, to eleven antibacterials by agar dilution. Additionally, we analyzed the results of routine E-testing during 2005-2008. Doxycycline was the most active tetracycline with (MIC₉₀ of 1 and 8 mg/L for ureaplasmas and M. hominis, respectively. Significantly more M. hominis isolates (approximately 10-13%) than ureaplasmas (approximately 1-3%) were resistant to tetracyclines. Ofloxacin was effective against both species (>95% susceptibility). Ciprofloxacin was moderately active against M. hominis and less active against ureaplasmas (70.3% and 35.2% susceptibility, respectively). Clarithromycin and josamycin were the most potent macrolides (MIC₉₀ of 0.5 mg/L) against ureaplasmas. Erythromycin had the lowest activity (MIC₉₀ of 8 mg/L) against ureaplasmas like clindamycin which was the most potent agent against M. hominis. Cross-resistance was found between tetracyclines (53-93%), macrolides and erythromycin (70-100%), and between erythromycin and ciprofloxacin (43-55%). M. hominis became more resistant to tetracyclines and fluoroquinolones between 1989 and 2004, although there was little change during 2005-2008. Ureaplasmas became more resistant to cipfloxacin during 1997 – 2004 and showed high resistance rates to erythromycin during 1989-2008. Doxycycline is still the drug of first-choice for the treatment of ureaplasmal infections and may be used for co-infection with M. hominis.</p>","PeriodicalId":504942,"journal":{"name":"Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases","volume":" ","pages":"1649-55"},"PeriodicalIF":14.2,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39970030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-10-01DOI: 10.1111/j.1469-0691.2009.03160.x
L Fuenzalida, S Blanco, C Prat, M Vivancos, M J Dominguez, J M Mòdol, C Rodrigo, V Ausina
Nasopharyngeal aspirates, collected during outbreaks, of the novel influenza A (H1N1) virus in Barcelona, were used to compare the accuracy of a rapid antigen-based test (Binax) with the real-time RT-PCR assay developed by the CDC. The sensitivity, specificity and positive predictive value of the rapid test are higher in patients less than 18 years old and during the acute stage of the epidemic than in adult patients.
{"title":"Utility of the rapid antigen detection BinaxNOW Influenza A&B test for detection of novel influenza A (H1N1) virus.","authors":"L Fuenzalida, S Blanco, C Prat, M Vivancos, M J Dominguez, J M Mòdol, C Rodrigo, V Ausina","doi":"10.1111/j.1469-0691.2009.03160.x","DOIUrl":"https://doi.org/10.1111/j.1469-0691.2009.03160.x","url":null,"abstract":"<p><p>Nasopharyngeal aspirates, collected during outbreaks, of the novel influenza A (H1N1) virus in Barcelona, were used to compare the accuracy of a rapid antigen-based test (Binax) with the real-time RT-PCR assay developed by the CDC. The sensitivity, specificity and positive predictive value of the rapid test are higher in patients less than 18 years old and during the acute stage of the epidemic than in adult patients.</p>","PeriodicalId":504942,"journal":{"name":"Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases","volume":" ","pages":"1574-6"},"PeriodicalIF":14.2,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39970355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：